[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201390403A1 - Способы получения фенилацетата l-орнитина - Google Patents

Способы получения фенилацетата l-орнитина

Info

Publication number
EA201390403A1
EA201390403A1 EA201390403A EA201390403A EA201390403A1 EA 201390403 A1 EA201390403 A1 EA 201390403A1 EA 201390403 A EA201390403 A EA 201390403A EA 201390403 A EA201390403 A EA 201390403A EA 201390403 A1 EA201390403 A1 EA 201390403A1
Authority
EA
Eurasian Patent Office
Prior art keywords
phenylacetate
methods
ornitin
obtaining
ornithine
Prior art date
Application number
EA201390403A
Other languages
English (en)
Other versions
EA028395B1 (ru
Inventor
Кейт Х. Андерсон
Джим Белинг
Кристин Хендерсон Дуган
Стивен Уильям Ватт
Питер Манини
Аттилия Фиджини
Original Assignee
Осера Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Осера Терапьютикс, Инк. filed Critical Осера Терапьютикс, Инк.
Publication of EA201390403A1 publication Critical patent/EA201390403A1/ru
Publication of EA028395B1 publication Critical patent/EA028395B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В изобретении предложены способы получения фенилацетата L-орнитина. Указанный способ может включать, например, смешивание галогенидной соли L-орнитина с фенилацетатом серебра. Способ также может включать получение фенилацетатной соли in situ.Заявка также относится к различным композициям, полученным согласно данным способам, содержащим кристаллические формы.
EA201390403A 2010-10-06 2011-10-05 Способы получения фенилацетата l-орнитина EA028395B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39058510P 2010-10-06 2010-10-06
PCT/US2011/054983 WO2012048043A1 (en) 2010-10-06 2011-10-05 Methods of making l-ornithine phenyl acetate

Publications (2)

Publication Number Publication Date
EA201390403A1 true EA201390403A1 (ru) 2013-09-30
EA028395B1 EA028395B1 (ru) 2017-11-30

Family

ID=45928120

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390403A EA028395B1 (ru) 2010-10-06 2011-10-05 Способы получения фенилацетата l-орнитина

Country Status (16)

Country Link
US (2) US8946473B2 (ru)
EP (1) EP2625162B1 (ru)
JP (1) JP6087284B2 (ru)
KR (1) KR101888215B1 (ru)
CN (1) CN103502203B (ru)
AU (1) AU2011312042B2 (ru)
BR (1) BR112013008054B1 (ru)
CA (1) CA2813563C (ru)
EA (1) EA028395B1 (ru)
ES (1) ES2720148T3 (ru)
IL (1) IL225512A (ru)
MX (1) MX360062B (ru)
NZ (1) NZ609191A (ru)
SG (1) SG189231A1 (ru)
TR (1) TR201903978T4 (ru)
WO (1) WO2012048043A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2537974T3 (es) 2004-11-26 2015-06-16 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para el tratamiento de la encefalopatía hepática
MX375111B (es) 2009-04-03 2025-03-06 Ocera Therapeutics Inc Fenil acetato de l-ornitina y métodos para elaborar el mismo.
CN104434894A (zh) 2009-06-08 2015-03-25 Ucl商业有限公司 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能
US8946473B2 (en) 2010-10-06 2015-02-03 Ocera Therapeutics, Inc. Methods of making L-ornithine phenyl acetate
ES2769000T3 (es) 2014-11-24 2020-06-24 Ucl Business Ltd Tratamiento de enfermedades asociadas con la activación de células estrelladas hepáticas utilizando terapias reductoras de amoníaco
AU2016252382A1 (en) * 2015-04-20 2017-11-02 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
HK1249434A1 (zh) 2015-08-18 2018-11-02 Ocera Therapeutics, Inc. 使用與苯乙酸鹽和苯丁酸鹽中的至少一種組合的l-鳥氨酸治療和預防肌肉損失
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
WO2017083758A1 (en) * 2015-11-13 2017-05-18 Ocera Therapeutics, Inc. Formulation of l-ornithine phenylacetate
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CA3063134A1 (en) * 2017-05-11 2018-11-15 Ocera Therapeutics, Inc. Processes of making l-ornithine phenylacetate
CN111295187A (zh) 2017-08-14 2020-06-16 胺细拉健康公司 用于治疗肝脏疾病的氨基酸组合物
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
WO2024261477A1 (en) 2023-06-20 2024-12-26 Yaqrit Limited Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB965637A (en) 1962-04-23 1964-08-06 Tanabe Seiyaku Co L-ornithine l-aspartate
NL302572A (ru) 1962-12-27
GB1067742A (en) 1963-09-16 1967-05-03 Kyowa Hakko Kogyo Kk Process for the preparation of l-ornithine l-aspartate
ZA716628B (en) 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
US4100293A (en) 1974-04-15 1978-07-11 The Johns Hopkins University Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids
US3950529A (en) 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
US4228099A (en) 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4320146A (en) 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4352814A (en) 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
DE4020980C1 (ru) 1990-07-02 1991-09-26 Degussa Ag, 6000 Frankfurt, De
US5591613A (en) 1990-07-02 1997-01-07 Degussa Aktiengesellschaft Method for the preparation of D-arginine and L-ornithine
JP3127484B2 (ja) 1991-02-28 2001-01-22 味の素株式会社 肝炎治療薬
US5767086A (en) 1992-04-03 1998-06-16 Terrapin Technologies, Inc. Bone marrow stimulation by certain glutathione analogs
CA2144163A1 (en) 1992-09-09 1994-03-17 Fisons Limited Pharmaceutical packaging
US5571783A (en) 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
JP3273578B2 (ja) * 1993-09-21 2002-04-08 第一化学薬品株式会社 オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法
US5840891A (en) 1994-07-28 1998-11-24 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
WO1997030167A1 (en) 1996-02-13 1997-08-21 The Trustees Of The University Of Pennsylvania Method of treating liver disorders
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6258849B1 (en) 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
AU4778700A (en) 1999-05-21 2000-12-12 Takeda Chemical Industries Ltd. Liver function controlling agents
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
JP3211824B1 (ja) 2000-10-26 2001-09-25 味の素株式会社 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法
WO2002074302A1 (fr) 2001-03-15 2002-09-26 Riken Compositions d'acides amines utilisees pour ameliorer l'insuffisance hepatique
US6503530B1 (en) 2001-11-01 2003-01-07 Chunghee Kimberly Kang Method of preventing development of severe metabolic derangement in inborn errors of metabolism
US20030105104A1 (en) 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
CN1383815A (zh) 2002-05-08 2002-12-11 刘万忠 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法
US20040152784A1 (en) 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
WO2004019928A1 (ja) 2002-08-30 2004-03-11 Ajinomoto Co., Inc. 肝疾患治療剤
US20050059150A1 (en) 2003-09-17 2005-03-17 Becton, Dickinson And Company Environments that maintain function of primary liver cells
MXPA03009902A (es) * 2003-10-29 2005-05-03 Manuel Francisco Lara Och Jose Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio.
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
JP4954867B2 (ja) 2004-05-06 2012-06-20 オステオロジックス エイ／エス 有機金属塩類を製造するための高収率で迅速な合成法
EP1799759A1 (en) 2004-08-30 2007-06-27 Lunamed Inc. 4-phenylbutyric acid controlled-release formulations for therapeutic use
ES2537974T3 (es) 2004-11-26 2015-06-16 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para el tratamiento de la encefalopatía hepática
ME01879B (me) 2005-11-17 2014-12-20 Stabilna formulacija amorfnih perindopril soli, postupak njihove pripreme, posebno industrijske proizvodnje i njihova upotreba u terapiji hipertenzije
CN201421432Y (zh) * 2009-02-20 2010-03-10 山东师范大学 一种相干衍射成像处理装置
MX375111B (es) 2009-04-03 2025-03-06 Ocera Therapeutics Inc Fenil acetato de l-ornitina y métodos para elaborar el mismo.
CN104434894A (zh) 2009-06-08 2015-03-25 Ucl商业有限公司 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能
US8946473B2 (en) 2010-10-06 2015-02-03 Ocera Therapeutics, Inc. Methods of making L-ornithine phenyl acetate

Also Published As

Publication number Publication date
EP2625162A1 (en) 2013-08-14
US8946473B2 (en) 2015-02-03
WO2012048043A1 (en) 2012-04-12
TR201903978T4 (tr) 2019-04-22
JP2013542935A (ja) 2013-11-28
CA2813563A1 (en) 2012-04-12
EP2625162B1 (en) 2019-03-13
US20150133684A1 (en) 2015-05-14
EA028395B1 (ru) 2017-11-30
AU2011312042A1 (en) 2013-05-02
IL225512A (en) 2017-12-31
US20130211135A1 (en) 2013-08-15
NZ609191A (en) 2015-06-26
CA2813563C (en) 2019-02-26
US9260379B2 (en) 2016-02-16
IL225512A0 (en) 2013-06-27
ES2720148T3 (es) 2019-07-18
MX360062B (es) 2018-10-22
MX2013003764A (es) 2013-05-20
KR101888215B1 (ko) 2018-09-20
BR112013008054A2 (pt) 2016-06-14
BR112013008054B1 (pt) 2019-04-09
AU2011312042B2 (en) 2015-08-20
JP6087284B2 (ja) 2017-03-01
CN103502203B (zh) 2016-09-07
SG189231A1 (en) 2013-05-31
CN103502203A (zh) 2014-01-08
KR20140053807A (ko) 2014-05-08
EP2625162A4 (en) 2014-06-25

Similar Documents

Publication Publication Date Title
EA201390403A1 (ru) Способы получения фенилацетата l-орнитина
EA201291470A1 (ru) Замороженное кондитерское изделие
TW201231056A (en) Metal salt compositions
MY166637A (en) Method for producing ternesite
EA201391389A1 (ru) Кристаллы антител против склеростина и составы на их основе
MX2013002603A (es) Composicion de aceite y metodo para producir la misma.
WO2012103279A3 (en) Methods and compositions for the synthesis of multimerizing agents
EA201491195A1 (ru) Способ получения композиции, содержащей галактоолигосахариды
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
EA201391180A1 (ru) Способ получения оптически активных производных дигидробензофурана
EA201391489A1 (ru) Композиции со сниженной вязкостью
WO2014086982A3 (en) Stable metal compounds, their compositions and methods of their use
EA201490756A1 (ru) Разагилина цитрамид
MY166797A (en) Geopolymer activator composition and geopolymer binder, paste and concrete prepared therewith
NZ607149A (en) Galacto-oligosaccharide-containing composition and a method of producing it
MX2014002996A (es) Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
MX2013013891A (es) Sistema y metodo de tratamiento de agua anti-incrustaciones.
CY1118079T1 (el) Μεθοδος παρασκευης του αλατος l-αργινινικης περινδοπριλης
EA201391056A1 (ru) Гетероарильные соединения в качестве лигандов 5-htрецептора
EA201171466A1 (ru) Композиция неслеживающейся соли, способ ее получения и использование
IN2014MN01671A (ru)
EA201391214A1 (ru) Композиции, содержащие алкилалкоксисульфонаты, для производства термостабильных пен
EA201200820A1 (ru) Способ синтеза промежуточных продуктов, применимых для получения замещенных индазолов и азаиндазолов
UA114082C2 (xx) Спосіб одержання водорозчинних селеноглікопротеїнів та композиція, що їх містить
PH12015500061A1 (en) Method for preparing substituted triazolopyridines

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM